Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Susan Jacobi (NPI 1225143316)

Field	Value
Entity Type	Individual
Organization	Susan Jacobi
Address	8421 Plum Dr
City	Urbandale
State	IA
ZIP	50322
Taxonomy	Rheumatology Physician
NPI Enumerated	August 20, 2006

Payer Source	Total Paid
Medicare	$942.5K
Medicaid	$0

Key Findings

This provider has $942.5K in lifetime Medicare revenue with no Medicaid billing on file, making their practice effectively single-payer Medicare in scale. The absence of any Medicaid claims indicates Medicare dominates the payer mix and that Medicaid does not contribute to this provider’s recorded public-payer revenue footprint.

Revenue is highly concentrated in physician-administered specialty drugs: the top three Medicare codes (J0129, J0717, J1745) together account for 55.9% of total Medicare revenue. Each of those codes is a billed biologic or infused/subcutaneously administered agent, which suggests the practice operates a biologic infusion/administration service line as a primary revenue driver rather than a purely office-based evaluation-and-management model.

J0129 is the single largest revenue code at $207.4K (22.2% of Medicare revenue) but ranks in the 34th percentile nationally for volume, indicating this provider generates substantial revenue from abatacept relative to their peers without being a high-volume national outlier. This suggests focused selection or patient mix that yields outsized revenue contribution from this particular biologic despite typical claim counts compared with peers.

J0717 ($161.6K, 17.3% of Medicare revenue) and J1745 ($152.9K, 16.4% of Medicare revenue) are also major revenue contributors and sit at the 40th and 80th national percentiles respectively, which positions the provider as a modest-to-strong regional supplier for certolizumab pegol and infliximab administration. The 80th percentile ranking for J1745 indicates relatively higher-than-typical billing volume for infliximab compared with national peers, consistent with an infusion capability.

Evaluation-and-management codes contribute a minority of revenue: 99214 accounts for $46.2K (5.0% of Medicare revenue) and 99213 for $18.9K (2.0%), and both sit at high national percentiles for volume (92nd and 87th). This mix—E/M visits present but smaller revenue share than biologic drug administration—supports a business model where office visits support and triage therapy but the primary revenue comes from drug administration.

The provider reports a broad set of supportive services tied to infusion care: chemotherapy administration codes (96413, 96401, 96415) and infusion initiation (96365) appear in the top codes, collectively reflecting ongoing infusion and injection workflows. These ancillary procedure codes and frequent lab codes (82565, 85027, 82306, 84450, 84460, 82040) indicate in-office monitoring and lab testing are integrated into the care pathway for patients receiving biologics or infusion therapies.

Competitive standing is mixed across codes: several lab and routine procedure codes rank at very high national percentiles (e.g., 82565 at the 96th percentile, 36415 at the 94th), indicating higher-than-typical volumes for phlebotomy and lab services, while key biologic codes vary from below-median (J0129 at 34th percentile) to above-median (J1745 at 80th percentile). Overall, the provider is not a dominant national player across all codes but appears regionally strong in certain infusion drugs and consistently high-volume for routine practice support services.

The NPI enumeration date is 2006-08-20 (approximately 20 years ago), signaling long tenure in the Medicare program. This longevity supports experience in managing infused biologic therapy and associated billing workflows over a sustained period, which aligns with the durable revenue contributed by administration codes and follow-up E/M visits.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

46 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	6,100	$30	$207.4K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	40,400	$1	$161.6K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	5,880	$30	$152.9K
J0897	Injection, denosumab, 1 mg	7,380	$20	$132.8K
J3111	Injection, romosozumab-aqqg, 1 mg	14,490	$10	$115.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	560	$80	$46.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	250	$100	$23.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	310	$60	$18.9K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	300	$50	$16.4K
77080	The provider performs an imaging procedure, called dual–energy X–ray absorptiometry (DXA), of one or more bony areas on the trunk to determine the bone mineral density (BMD) and whether the patient…	310	$20	$7.5K

Showing 1–10 of 46

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 46 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Susan Jacobi — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

46 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	6	20	5,950	$30	$218.3K
J3111	7	20	12,180	$10	$112K
J0717	3	20	23,500	$1	$93.9K
J1745	3	20	3,460	$30	$92.3K
J0897	26	190	1,920	$20	$74.1K
96413	32	80	210	$90	$24K
99214	394	4,690	100	$70	$14.4K
99490	166	330	130	$40	$9K
99213	548	4,740	100	$50	$8K
96401	5	40	90	$50	$7.4K

Showing 1–10 of 46

Nearby Providers

Other providers in the same ZIP code as Susan Jacobi, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mosaic	IA	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$177.4M
The Respite Connection, Inc.	IA	Community/Behavioral Health Agency	$0	$38.1M
Unitypoint At Home	IA	Durable Medical Equipment & Medical Supplies	$0	$16.5M
Unitypoint At Home	IA	Home Infusion Therapy Pharmacy	$0	$15.4M
New Beginnings Counseling Service, LLC	IA	Community/Behavioral Health Agency	$0	$6.3M
A-1 Iowa Dental PLLC	IA	Dentist	$0	$5.4M
Urbandale Community School District	IA	Local Education Agency (LEA)	$0	$4.4M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$3.9M
Acs Medical LLC	IA	Durable Medical Equipment & Medical Supplies	$0	$3.6M
Wellserve Health, Inc.	IA	Community/Behavioral Health Agency	$0	$2.8M

Susan Jacobi — Billing Profile & Reimbursement Data

Sign up for Susan Jacobi — Billing Profile & Reimbursement Data policy alerts

Susan Jacobi — Billing Profile & Reimbursement Data

Sign up for Susan Jacobi — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Nearby Providers

Frequently Asked Questions

References